Alpha Teknova (TKNO) – Research Analysts’ Weekly Ratings Updates

Alpha Teknova (NASDAQ: TKNO) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – Alpha Teknova was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/6/2026 – Alpha Teknova was upgraded by Zacks Research to “hold”.
• 8/5/2026 – Alpha Teknova is now covered by Roth Capital. They set a “buy” rating and a $7.00 price target on the stock.
• 8/5/2026 – Alpha Teknova is now covered by Roth Capital. They set a “buy” rating and a $7.00 price target on the stock.
• 7/17/2026 – Alpha Teknova had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.